» Articles » PMID: 7073268

Pharmacokinetics of Ceforanide

Overview
Specialty Pharmacology
Date 1982 Feb 1
PMID 7073268
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The pharmacokinetic of ceforanide, a new parenteral cephalosporin antibiotic, were examined at intravenous and intramuscular doses of 250, 500, and 1,000 mg in healthy male volunteers. Over the above dosing range, ceforanide pharmacokinetics were essentially linear, with plasma clearances varying from 2.2 to 2.5 liters/h. The best present overall estimate of the drug's half-life was 2.9 h. Intramuscular ceforanide was 100% bioavailable, Peak intravenous serum levels were 39, 71, and 135 micrograms/ml at the end of 30-min infusions of 250, 500, and 1,000 mg; after intramuscular injections of 250, 500, and 1,000 mg, the respective peak serum levels were 21, 38, and 69 micrograms/ml. From 80 to 85% of the above doses were eliminated as unchanged.

Citing Articles

Twice-daily intramuscular ceforanide therapy of Staphylococcus aureus endocarditis in parenteral drug abusers.

Greenman R, Arcey S, Gutterman D, Zweig R Antimicrob Agents Chemother. 1984; 25(1):16-9.

PMID: 6703681 PMC: 185425. DOI: 10.1128/AAC.25.1.16.


In vitro antimicrobial activity of eight new beta-lactam antibiotics against penicillin-resistant Neisseria gonorrhoeae.

Kerbs S, Stone Jr J, Berg S, HARRISON W Antimicrob Agents Chemother. 1983; 23(4):541-4.

PMID: 6407392 PMC: 184696. DOI: 10.1128/AAC.23.4.541.


Performance of a diffusional clearance model for beta-lactam antimicrobial agents as influenced by extravascular protein binding and interstitial fluid kinetics.

Fleishaker J, McNamara P Antimicrob Agents Chemother. 1985; 28(3):369-74.

PMID: 4073859 PMC: 180255. DOI: 10.1128/AAC.28.3.369.


Intraoperative ceforanide pharmacokinetics and protein binding.

DiPiro J, Bayoumi S, Vallner J, NESBIT R, Gokhale R, Rissing J Antimicrob Agents Chemother. 1985; 27(4):487-90.

PMID: 4004190 PMC: 180080. DOI: 10.1128/AAC.27.4.487.


Ceforanide. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Lackner T, Monk J Drugs. 1987; 34(4):411-37.

PMID: 3315624 DOI: 10.2165/00003495-198734040-00001.

References
1.
Loo J, RIEGELMAN S . Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion. J Pharm Sci. 1970; 59(1):53-5. DOI: 10.1002/jps.2600590107. View

2.
Leitner F, MISIEK M, PURSIANO T, BUCK R, Chisholm D, DeRegis R . Laboratory evaluation of BL-S786, a cephalosporin with broad-spectrum antibacterial activity. Antimicrob Agents Chemother. 1976; 10(3):426-35. PMC: 429765. DOI: 10.1128/AAC.10.3.426. View

3.
Smyth R, Pfeffer M, Glick A, Van Harken D, Hottendorf G . Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin. Antimicrob Agents Chemother. 1979; 16(5):615-21. PMC: 352915. DOI: 10.1128/AAC.16.5.615. View

4.
Pfeffer M, GAVER R, Van Harken D . Human pharmacokinetics of a new braod-spectrum parenteral cephalosporin antibiotic, ceforanide. J Pharm Sci. 1980; 69(4):398-403. DOI: 10.1002/jps.2600690409. View

5.
Shadomy S, Wagner G, Carver M . In vitro and in vivo studies with BL-S786, cefoxitin, and cefamandole. Antimicrob Agents Chemother. 1978; 13(3):412-5. PMC: 352254. DOI: 10.1128/AAC.13.3.412. View